(Information sent by the signatory company)
BOSTON and MILAN, December 1, 2023/PRNewswire/ -- Allotex Inc. and SpA, a leading biologics and devices company specializing in vision correction therapies, is pleased to announce that Junson Capital has joined its union of investors. This additional capital will help support the expansion of the company's manufacturing facilities in preparation for market introduction and clinical trials in the US.
Allotex's innovative approach uses laser-shaped human corneal allografts to reshape the cornea for the treatment of presbyopia, restoring lost reading vision caused by the natural aging process. With hundreds of millions of people around the world looking for a safe, effective and long-lasting alternative to reading glasses and contact lenses, the company is poised to make a major impact on the vision care market.
Dr. David Muller, Founder and CEO of Allotex, commented on the company's progress, saying, "This financing will allow Allotex to introduce our groundbreaking technology in Europe and Japan in early 2024 while actively working with the FDA to initiate clinical trials in the United States as soon as possible. The additional capital will help support the necessary expansion of our production facilities to increase capacity and ensure a steady supply of products."
Dr. David Muller, Founder and CEO of Allotex, commented on the company's progress, saying: "This funding will allow Allotex to introduce our innovative technology in Europe and Japan in early 2024 as we actively work with the FDA to initiate clinical trials. in the United States as soon as possible. The additional capital will help support the necessary expansion of our production facilities to increase capacity and ensure a steady supply of products."
John White, Allotex board member representing KCK MedTech, commented: “Our published safety and efficacy results, along with our 4-year follow-up, will drive market acceptance for both patients and refractive surgeons. "Surgeons have relied on the use of human corneal allografts for more than 70 years and we are excited about the potential of our technology to restore reading vision to millions of people who have age-related presbyopia."
Junson Capital has joined existing investors including KCK MedTech, Panakes, Supernova Invest and Exor Ventures to complete the Series B financing. Wei Shen, representing Junson Capital, shared his excitement about joining the investor syndicate and stated: "We are excited to partner with Allotex and contribute to the advancement of their innovative therapies. The potential to have a significant impact on the global vision correction market is evident and we look forward to being part of this transformative journey." Junson Capital is a global investment manager with a long-standing dedication to leading and investing in disruptive technology and healthcare across venture capital, private equity, public markets, real estate and alternatives. Allotex had the advice of Cukierman
About Allotex Inc. Allotex Inc. is a pioneering biologics and device company focused on the development of innovative therapeutic solutions for vision correction. By using precisely shaped human corneal allografts, Allotex creates a natural, removable inlay, offering patients a safe, permanent vision correction option. Committed to advancing vision correction, Allotex is dedicated to improving the lives of people affected by presbyopia and other refractive disorders of the human eye.
For more information about Allotex, visit www.allotex.com or contact Travis Henry (travis.henry@allotex.com).
Logo - https://mma.prnewswire.com/media/2289846/Allotex_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/allotex-anuncia-nuevo-inversor-y-ampliacion-de-instalaciones-de-produccion-302003407.html
